Cas:151835-56-2 1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene manufacturer & supplier

Chemical Name:1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene

CAS.NO:151835-56-2

Synonyms:MFCD05664302;2,5-Bis(bromomethyl)-1-methoxy-4-octyloxybenzene

Molecular Formula:C₁₇H₂₆Br₂O₂

Molecular Weight:422.19500

HS Code:2909309090

Physical and Chemical Properties:

Melting point:97.2-99.3ºC(lit.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:18.46000

Exact Mass:420.03000

LogP:6.22430

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1759 8/PG 3

Packing Group:

Contact us for information like MFCD05664302 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-Bis(bromomethyl)-1-methoxy-4-octyloxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD05664302 Use and application,2,5-Bis(bromomethyl)-1-methoxy-4-octyloxybenzene technical grade,usp/ep/jp grade.

Related News: Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene manufacturer AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene supplier A U.S. Senator, New Jersey Democrat Bob Menendez, called allegations of manufacturing irregularities and records tampering at the Branchburg plant troubling. Menendez has sponsored a bill calling for a non-partisan, independent COVID-19 Commission to examine the U.S. pandemic response, including government contracts with companies. 1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene vendor Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. 1,4-bis(bromomethyl)-2-methoxy-5-octoxybenzene factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.